Physician profile
Farzad Adib
NPI 1558745869
$475.67
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $15.62 · 2021: $94.54 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $108.41 | 2022 | |
| Biocryst US Sales Co., LLC | $94.54 | 2021 | |
| Glaxosmithkline, LLC. | $85.00 | 2019 | |
| Csl Behring | $74.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.74 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $27.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2019 | |
| Akcea Therapeutics, INC. | $19.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzad Adib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.